Mironova Labs

DMTMM for Peptide Manufacturing

No guanidinylation, water-tolerant, scale economics

For process chemists evaluating coupling reagents at manufacturing scale

Request R&D Evaluation Kit DMTMM Science Hub

≥99%

Purity (HPLC)

~$730M

Reagent Market (2024)

3 Salts

Cl / BF₄ / PF₆

50 kg+

Production Scale

Supported by peer-reviewed research·≥99% purity (HPLC)·US-manufactured (Fairfield, NJ)·Research to 50 kg+ scale·Peer-reviewed evidence

DMTMM is a triazine-based coupling reagent that activates carboxylic acids without the guanidinylation side reactions associated with uronium reagents like HATU and HBTU. Mironova manufactures all three DMTMM salt forms (Cl, BF₄, PF₆) at ≥99% purity from our Fairfield, NJ facility. This page covers the evidence, application protocols, and products relevant to peptide manufacturing at scale.

DMTMM Science Hub Coupling Reagent Catalog

Challenges & Solutions

Your Challenge. Our Answer.

We understand the specific problems you face — and we built solutions for each one.

The Problem

Guanidinylation side products cap peptide chains and reduce crude purity with uronium reagents (HATU, HBTU)

Mironova’s Answer

DMTMM activates via a triazine mechanism — structurally incapable of guanidinylation, avoiding guanidinium-type impurities associated with uronium reagents

Zero guanidinylation by mechanism

The Problem

HOBt-based coupling systems (PyBOP) are classified as explosives for transport, complicating procurement and plant siting

Mironova’s Answer

DMTMM thermal onset is 163 °C with −1 956 J/g — classified "Use with Caution," not shock-sensitive. No HOBt required.

163 °C thermal onset

The Problem

Catalog-grade reagents at 95% purity increase impurity burden and purification cycles at multi-kg scale

Mironova’s Answer

Mironova supplies all DMTMM salts at ≥99.0% (HPLC) from our US facility — 80% less impurity mass vs 95% material

80% less impurity mass

The Problem

Lipidation steps for GLP-1 peptides (semaglutide, tirzepatide class) are quality-critical and sensitive to coupling-reagent choice

Mironova’s Answer

DMTMM mechanistically avoids guanidinylation in fatty diacid attachment. No published manufacturing data yet — evaluation kits available.

Published Research

Published Evidence

Key findings from peer-reviewed literature relevant to your application.

BF₄ "Superactive Ester" in SPPS

80–100% coupling yield with high enantiomeric purity

Reported 80–100% coupling yields with high enantiomeric purity under optimized conditions. Faster fragment synthesis than TBTU or HATU reported; purer crude than TBTU or PyBOP in automated SPPS.

Kamiński et al., J. Am. Chem. Soc. 2005

Thermal Safety Profile

Classified "Use with Caution" — safest tier among active coupling reagents

DSC screening of 45 coupling reagents: DMTMM onset 163 °C, −1 956 J/g, not shock-sensitive. HATU/HBTU classified "Least Preferred." HOBt dry: propagates detonation.

Sperry et al., Org. Process Res. Dev. 2018

No Guanidinylation Mechanism

Uronium/guanidinium reagents produce guanidino side products that cap peptide chains. DMTMM lacks the uronium moiety entirely.

Vrettos et al., RSC Advances 2017

DMTMM in GLP-1 Class Peptide Assembly

Demonstrated in tirzepatide fragment coupling

DMTMM used in liquid-phase C-terminal assembly of tirzepatide, demonstrating utility for GLP-1 class peptide fragment coupling.

Agrawal et al., Org. Process Res. Dev. 2025

Peptide Reagent Market Growth

Peptide synthesis reagents market estimated at ~$730M (2024) growing to ~$1.5B by 2034, driven by GLP-1 and peptide therapeutic pipelines.

Global Market Insights; Mironova analysis

Market Context

GLP-1 Demand Is Reshaping Peptide Manufacturing

The GLP-1 receptor agonist franchise grew from an estimated ~$12B (2020) to over $76B (2025, Novo Nordisk + Lilly combined), driving unprecedented demand for peptide coupling reagents. Peptide synthesis reagent spend is projected at ~$730M (2024), growing to ~$1.5B by 2034. Process chemists are under pressure to qualify reagents that reduce impurity burden, improve safety profiles, and scale predictably — exactly where DMTMM’s triazine mechanism offers structural advantages over uronium-based alternatives.

Semaglutide and tirzepatide alone drove >60% of GLP-1 franchise revenue in 2025
CDMOs are adding dedicated peptide lines, creating new coupling reagent qualification cycles
Regulatory agencies flagging HOBt-based reagent safety in new facility inspections

Novo Nordisk/Lilly disclosures; Global Market Insights; Mironova analysis

$76B+

GLP-1 franchise (2025 est.)

~$1.5B

Reagent market by 2034

80%

Less impurity mass at 99% vs 95%

Product Catalog

SPPS & Lipidation Conditions

NMP or DMF/NMP mixtures are recommended. Note that the BF₄ salt has limited solubility in pure DMF and may require optimized mixtures for complete dissolution during automated SPPS.

Use 1.5–3.0 equivalents relative to the amino acid for optimal coupling efficiency without excessive reagent consumption.

Reactions proceed efficiently at room temperature (20–25 °C) with a typical cycle time of 30–60 minutes per coupling.

NMM or collidine are the preferred bases. Avoid DIPEA as it can increase the rate of epimerization during activation.

For full coupling protocols, comparative racemization studies, and peer-reviewed citations, please visit our DMTMM Science Hub.

Why Mironova

Your Advantage with Mironova

99%+ Purity Standard

All three DMTMM salts supplied at ≥99.0% by HPLC. At manufacturing scale, upgrading from 95% to 99% purity eliminates 80% of reagent-derived impurity mass.

US Manufacturing

Produced in Fairfield, NJ with full analytical documentation (HPLC, NMR, MS, CoA). Domestic supply reduces lead-time risk for US-based CDMOs.

Three-Salt Portfolio

Cl for aqueous systems, BF₄ for SPPS, PF₆ for hindered couplings. One supplier, one qualification pathway, full workflow coverage.

R&D to 50 kg+ Scale

Consistent quality from evaluation kits through production campaigns. No re-qualification between scales.

Request Technical Data

Get product specifications, CoA samples, and pricing for your evaluation.

FAQ

Frequently Asked Questions

Common technical questions about this product line, answered by our scientific team.

HATU is effective for hindered couplings but carries guanidinylation risk, thermal sensitivity (classified “Least Preferred” per Sperry 2018), and requires HOBt-free sourcing for transport. DMTMM is positioned where water tolerance, safety profile, or cost qualification for specific steps matter — particularly lipidation and scale manufacturing.

Not as a universal swap. The recommended approach is to evaluate DMTMM on one quality-critical amidation step (e.g., a lipidation or fragment coupling), demonstrate performance parity or improvement, then expand scope based on process data.

DMTMM salts should be stored at 2–8 °C under inert atmosphere. In solution, stability varies by solvent — NMP and DMF/NMP mixtures are recommended. Avoid prolonged storage in DMSO or pure DMF where hydrolysis rates increase.

Published SPPS data (Kamiński et al., JACS 2005) show high enantiomeric purity with BF₄ using NMM as base. Avoid DIPEA, which can increase epimerization risk. Performance should be verified for your specific substrate under your conditions.

Yes. DMTMM has been used in liquid-phase C-terminal assembly of tirzepatide (Agrawal et al., Org. Process Res. Dev. 2025). Its triazine mechanism avoids guanidinylation during fatty diacid attachment. Evaluation kits for lipidation workflows are available.